Calamos Advisors’s Orion Biotech Opportunities Corp. Warrant ORIAW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-75,000
Closed -$5.29K 1186
2023
Q1
$5.29K Hold
75,000
﹤0.01% 1098
2022
Q4
$12.3K Hold
75,000
﹤0.01% 1079
2022
Q3
$13K Buy
+75,000
New +$16.2K ﹤0.01% 1150

Calamos Advisors's ORIAW Position: Q2 2023 in Review

Calamos Advisors sold out of Orion Biotech Opportunities Corp. Warrant (ORIAW) in Q2 2023, closing a stake of 75,000 shares — an estimated $5.29K sold.

Calamos Advisors first reported a position in ORIAW in Q3 2022 and held it in 3 quarters. The position peaked at $13K in Q3 2022. 0 funds tracked by Wall St. Rank hold ORIAW as of Q2 2023.

  • Calamos Advisors reported no remaining Orion Biotech Opportunities Corp. Warrant position as of Q2 2023 after selling out during the quarter.
  • Calamos Advisors sold 75,000 Orion Biotech Opportunities Corp. Warrant shares in Q2 2023, an estimated $5.29K.
  • Calamos Advisors first reported a position in Orion Biotech Opportunities Corp. Warrant in Q3 2022 and held it in 3 quarters.
  • Calamos Advisors's Orion Biotech Opportunities Corp. Warrant position peaked at $13K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Warrant as of Q2 2023.

Based on Calamos Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.